Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study

BACKGROUND: There is no consensus on the optimal regimen for unresectable recurrent hepatocellular carcinoma (HCC), so this retrospective study aimed to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and PD‐1 inhibitors (T‐L‐P) versus TACE combine...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wei‐Jun, Liu, Zong‐Han, Wang, Kang, Yu, Hong‐Ming, Cheng, Yu‐Qiang, Xiang, Yan‐Jun, Feng, Jin‐Kai, Zhou, Li‐Ping, Zhou, Hong‐Kun, Pan, Wei‐Wei, Guo, Wei‐Xing, Shi, Jie, Cheng, Shu‐Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242311/
https://www.ncbi.nlm.nih.gov/pubmed/36999793
http://dx.doi.org/10.1002/cam4.5880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242311/
https://www.ncbi.nlm.nih.gov/pubmed/36999793
http://dx.doi.org/10.1002/cam4.5880

Ejemplares similares